Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects

Clin Rheumatol. 2009 Mar;28(3):347-50. doi: 10.1007/s10067-008-1062-2. Epub 2008 Dec 6.

Abstract

Systemic sclerosis (SSc) is an autoimmune disease which involves the skin, as well as several internal organs. Most therapies available in this disease are symptomatic. Authors present a case of diffuse SSc with progressive disease not responding to currently available treatments. Therefore a 12-month protocol of repeated plasmapheresis and high-dose intravenous immunoglobulin treatment was administered with good clinical efficacy. Apart from monitoring the clinical symptoms throughout the treatment, authors also assessed a number of humoral and cellular immunolaboratory markers in order to obtain information on the immunomodulatory effects of this combined treatment in SSc.

Publication types

  • Case Reports

MeSH terms

  • Follow-Up Studies
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Male
  • Plasmapheresis*
  • Scleroderma, Systemic / pathology
  • Scleroderma, Systemic / physiopathology
  • Scleroderma, Systemic / therapy*
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous